Exclusive winter update from Verantos
Winter 2019 newsletter
Exclusive winter update from Verantos
Welcome to the first newsletter from Verantos!
As the market leader in electronic health record (EHR)-based studies for regulatory and reimbursement use, Verantos runs studies no one else can and achieves regulatory-grade accuracy.
In our quarterly newsletters, we plan to share industry news and company updates to keep you abreast of the latest developments in real world evidence. For now, we wish you a very safe and happy holiday season!
The Verantos Team
Verantos in the news
National Science Foundation announces award on pragmatic clinical trials
The National Science Foundation has awarded Verantos a grant to develop artificial intelligence technology that extracts clinical outcomes from real-world EHR data, enabling pragmatic clinical trials and advancing high-validity real-world evidence to improve patient care.
Read the full release
AI tools enable Verantos to provide more accurate RWE data for regulatory use
Verantos introduced a commercial service that uses AI, natural language processing, and machine learning to transform EHR data into high-validity real-world evidence. The platform enables precise patient identification, subgroup analysis, and credible observational studies to support new drug indications and regulatory decisions.
Read the article
Verantos announces EHR-based study solution
Verantos launched its solution for real-world evidence studies, combining structured and unstructured EHR data with artificial intelligence to deliver deep clinical insights and high-validity evidence for life sciences organizations.
Read moreOther Real World Evidence Updates
On December 6, 2018, the FDA released a new Framework for the Real World Evidence (RWE) Program to apply across the agency's drug and biologic review programs. Importantly, the new framework notes that leveraging real world data to improve regulatory decisions is a key strategic priority for the agency. The new guideline will help the agency and industry evaluate the potential use of RWE to support regulatory decisions that have visible outcomes for consumers.
For more information, read the Statement from FDA Commissioner Scott Gottlieb, M.D.